CDKN2A and neoplasm: The fifth edition of the World Health Organization (WHO) Classification of Tumors of the CNS (WHO CNS5) redefined adult diffuse gliomas by emphasizing the diagnostic and prognostic significance of molecular markers, including IDH mutations, 1p/19q co-deletion, and deletions of cyclin-dependent kinase inhibitors 2A and 2B (CDKN2A/B), which are commonly used in clinical practice [2,3].